Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
نویسندگان
چکیده
منابع مشابه
Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
Advanced-stage primary cutaneous T-cell lymphoma has an unfavorable prognosis and low survival rates. Aggressive treatment with chemotherapy is not curative and causes considerable side effects. The combination of bexarotene and denileukin diftitox is associated with an acceptable safety profile and a likely synergistic effect because bexarotene is capable of modulating expression of IL-2 recep...
متن کاملDenileukin diftitox for the treatment of cutaneous T-cell lymphoma
Cutaneous T-cell lymphoma/mycosis fungoides (CTCL/MF) is a rare lymphoproliferative disorder which can present as an indolent or as an aggressive process involving skin, lymph nodes, and blood. In stages IA, IB and IIA, it is usually managed with topical medications and phototherapy. If there is progression despite application of these treatments, or if the patient presents with a higher stage ...
متن کاملA phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Denileukin diftitox, a genetically engineered fusion protein combining the enzymatically active domains of diphtheria toxin and the full-length sequence for interleukin-2 (IL-2), efficiently targets lymphoma cells expressing the high-affinity IL-2 receptor (IL-2R) consisting of the alpha/p55/CD25, beta/p75/CD122, and gamma/p64/CD132 chains. In vitro studies demonstrated that the retinoid X rece...
متن کاملAdverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin lymphoma with predominant skin manifestations and a relatively indolent course at early stages, but it can be fatal in advanced settings. In the absence of cure, the goal of therapy for CTCL is to induce long-term remissions without further compromising a patient's immune system or quality of life. Denileukin diftitox (DD) is a fusion prote...
متن کاملPrimary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox
CLS: capillary leak syndrome CR: complete remission CTCL: cutaneous T-cell lymphoma DD: denileukin diftitox pcALCL: primary cutaneous anaplastic large-cell lymphoma Treg: T-regulatory cell INTRODUCTION Denileukin diftitox (DD) is a recombinant fusion protein that consists of the interleukin-2 molecule conjugated to the catalytic domain of diphtheria toxin. It targets cells expressing the high-a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports in Dermatology
سال: 2011
ISSN: 1662-6567
DOI: 10.1159/000324185